Apart from the two "Docs", there is someone else I know who will be very upset if Remestemcel_L is approved for GvHD. Look at the proportion of Incyte's revenue that is attributable to Jakafi (ruxolitinib). The Jakafi revenue ($2.5B) is not wholly attributable to GvHD sales, but a very large part of it is:
Cell Therapy News/Articles, page-16451
-
- There are more pages in this discussion • 1,540 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.010(1.01%) |
Mkt cap ! $1.158B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $1.555M | 1.548M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 104719 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 59081 | 30 |
View Market Depth
| Last trade - 12.28pm 15/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |